|
|
Trouble in Trialville: Plans for Post-DES Clopidogrel Trial Get Bogged Down Over Trial Design, Leade
|
| Link ID |
4800 |
| Title |
Trouble in Trialville: Plans for Post-DES Clopidogrel Trial Get Bogged Down Over Trial Design, Leade |
| Url |
http://www.medscape.com/viewarticle/572904?src=rss |
| Description |
Duke researchers designed the CODA trial to determine optimal clopidogrel duration post-DES but also to "evolve the regulatory landscape" for dealing with complicated device-drug regulatory approvals. But researchers, government agencies, and industry sponsors cannot necessarily agree on the trial design. Meanwhile, MATRIX registry results reinforce the urgent need for randomized clinical trial data. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
Apr 12, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 3. |
FDA Approvals: Diovan, Renvela, Humate-P
|
|
|
The FDA has approved an expanded indication for valsartan tablets, sevelamer carbonate tablets, and new storage conditions for factor VIII/von Willebrand factor complex intravenous injection. Medscape Medical News
|
| 5. |
ARBs Unable to TRANSCEND Placebo in High-Risk Patients
|
|
|
The angiotensin-receptor blocker telmisartan has fared no better than placebo in TRANSCEND in patients at high-risk of cardiovascular disease unable to tolerate ACE inhibitors, seemingly providing more questions than answers. Heartwire
|
|
|
